England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
NHS England已提议分阶段推出曲塞帕肽，这是一种前景看好的减肥药物，以使最有可能取得重大临床疗效的患者受益。
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:LLY), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S' (NYSE:NVO) and Ozempic (semaglutide).
名为Mounjaro的Tirzepatide由礼来公司（纽约证券交易所代码：LLY）生产，在临床试验中显示出显著成果。与诺和诺德A/S（纽约证券交易所代码：NVO）和Ozempic（索玛鲁肽）等现有疗法相比，它具有更大的减肥效果。
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
在SurMount-4试验中，患者在36周内平均减轻了20.9％的体重。
Also Read: Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals.
另请阅读：研究显示，像Ozempic这样的流行减肥药物在临床试验承诺与实际使用之间存在差距。
The plan, currently under consultation, aims to test various medication delivery models before expanding its availability.
该计划目前正在磋商中，旨在在扩大其可用性之前测试各种药物交付模式。
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence (NICE), tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
根据美国国家健康与护理卓越研究所（NICE）独立委员会的指导方针草案，建议肥胖患者使用替塞帕肽，最高剂量的最高标价为每月122磅（合159.6美元）。
The phased launch will integrate tirzepatide into community-based services and digital health platforms to expand accessibility.
分阶段启动将把tirzepatide整合到社区服务和数字健康平台中，以扩大可及性。
The rollout will target up to 240,000 people in the first three years and evaluate cost-effective delivery models, including virtual clinics.
此次推出将在前三年针对多达24万人，并评估包括虚拟诊所在内的具有成本效益的交付模式。
Eligible patients will be categorized based on their BMI and related health conditions. Initially, those with a BMI above 40 and three or more weight-related conditions, such as hypertension and cardiovascular disease, will qualify.
符合条件的患者将根据其体重指数和相关健康状况进行分类。最初，体重指数高于40且有三种或更多与体重相关的疾病（例如高血压和心血管疾病）的人将符合资格。
Obesity is a significant challenge for the NHS, with annual treatment costs reaching 11.4 billion pounds ($14.91 billion).
肥胖是国民保健服务面临的重大挑战，每年的治疗费用达到114英镑（合149.1亿美元）。
According to the Health Survey for England 2022, about 64% of adults in the country are overweight or obese.
根据2022年英格兰健康调查，该国约有64％的成年人超重或肥胖。
The consultation period for the rollout plan is currently open, with final guidance from NICE expected later this year.
该推出计划的磋商期目前已开始，预计NICE将在今年晚些时候提供最终指导。
Earlier this week, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development, as the company inches closer to becoming the first pharma company in the $1 trillion club.
本周早些时候，礼来公司宣布投资45亿美元创建礼来药品铸造厂，这是一个新的先进制造和药物开发中心，因为该公司即将成为这个1万亿美元俱乐部中的第一家制药公司。
Price Action: LLY stock is down 0.23% at $883.56 at the last check Friday.
价格走势：在周五的最后一次支票中，LLY股价下跌0.23％，至883.56美元。
- Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses.
- Novo Nordisk/阿斯利康的制造合作伙伴Thermo Fisher因制造失误受到质疑。
Photo via Company
照片来自公司